iBio is a clinical-stage biotechnology company developing antibody therapies for obesity, cardiometabolic, and cardiopulmonary diseases. The company focuses on next-generation biologics designed to complement GLP-1 treatments by addressing muscle loss during weight loss, fat regain, and tolerability issues. iBio discovers and optimizes drug candidates using a proprietary AI drug discovery platform with tools for epitope design, antibody optimization, and bispecific antibody engineering. The company's lead clinical candidate is IBIO-600, an anti-myostatin antibody in Phase 1 trials intended to preserve lean muscle mass. Its preclinical pipeline includes IBIO-610, an anti-Activin E antibody designed for fat-selective weight loss, a bispecific antibody candidate targeting obesity and cardiopulmonary disease, and an amylin receptor agonist program. iBio also holds preclinical oncology assets available for out-licensing. As a pre-revenue company, iBio funds its operations through equity issuances and outsources all clinical manufacturing to contract research organizations. iBio's business model relies on advancing drug candidates through clinical development to achieve commercialization or secure out-licensing partnerships, as well as out-licensing its AI discovery platform across non-core therapeutic areas.